Research ArticleArticle
Alemtuzumab as Remission Induction Therapy in Behçet Disease: A 20-year Experience
Aladdin J. Mohammad, Rona M. Smith, Yok W. Chow, Afzal N. Chaudhry and David R.W. Jayne
The Journal of Rheumatology August 2015, jrheum.141344; DOI: https://doi.org/10.3899/jrheum.141344
Aladdin J. Mohammad
From the Department of Renal Medicine, Addenbrooke’s Hospital, Cambridge, UK; Department of Clinical Sciences, Rheumatology, Lund University, Lund, Sweden; Department of Medicine, Hospital Pantai Ayer Keroh, Melaka, Malaysia. Supported by the Cambridge Biomedical Research Centre and The Swedish Society of Medicine (Svenska Läkarsällskapet). A.J. Mohammad, MD, PhD, Department of Renal Medicine, Addenbrooke’s Hospital, and Department of Clinical Sciences, Rheumatology, Lund University; R.M. Smith, MA, MB BChir, MRCP, Department of Renal Medicine, Addenbrooke’s Hospital; Y.W. Chow, MD(USM), MRCP(UK), MRCPE, FRCP(Edinburgh), AM(MAL), Department of Medicine, Hospital Pantai Ayer Keroh Melaka; A.N. Chaudhry, MBBS, PhD, FRCP, FHEA, FACad MEd, Department of Renal Medicine, Addenbrooke’s Hospital; D.R. Jayne, MD, FRCP, Department of Renal Medicine, Addenbrooke’s Hospital. Address correspondence to Dr. A.J. Mohammad, Box 57, Renal Medicine, Addenbrooke’s Hospital, Hills Road, Cambridge, CB20QQ, UK. E-mail: aladdin.mohammad@med.lu.se. Accepted for publication June 9, 2015.
Rona M. Smith
From the Department of Renal Medicine, Addenbrooke’s Hospital, Cambridge, UK; Department of Clinical Sciences, Rheumatology, Lund University, Lund, Sweden; Department of Medicine, Hospital Pantai Ayer Keroh, Melaka, Malaysia. Supported by the Cambridge Biomedical Research Centre and The Swedish Society of Medicine (Svenska Läkarsällskapet). A.J. Mohammad, MD, PhD, Department of Renal Medicine, Addenbrooke’s Hospital, and Department of Clinical Sciences, Rheumatology, Lund University; R.M. Smith, MA, MB BChir, MRCP, Department of Renal Medicine, Addenbrooke’s Hospital; Y.W. Chow, MD(USM), MRCP(UK), MRCPE, FRCP(Edinburgh), AM(MAL), Department of Medicine, Hospital Pantai Ayer Keroh Melaka; A.N. Chaudhry, MBBS, PhD, FRCP, FHEA, FACad MEd, Department of Renal Medicine, Addenbrooke’s Hospital; D.R. Jayne, MD, FRCP, Department of Renal Medicine, Addenbrooke’s Hospital. Address correspondence to Dr. A.J. Mohammad, Box 57, Renal Medicine, Addenbrooke’s Hospital, Hills Road, Cambridge, CB20QQ, UK. E-mail: aladdin.mohammad@med.lu.se. Accepted for publication June 9, 2015.
Yok W. Chow
From the Department of Renal Medicine, Addenbrooke’s Hospital, Cambridge, UK; Department of Clinical Sciences, Rheumatology, Lund University, Lund, Sweden; Department of Medicine, Hospital Pantai Ayer Keroh, Melaka, Malaysia. Supported by the Cambridge Biomedical Research Centre and The Swedish Society of Medicine (Svenska Läkarsällskapet). A.J. Mohammad, MD, PhD, Department of Renal Medicine, Addenbrooke’s Hospital, and Department of Clinical Sciences, Rheumatology, Lund University; R.M. Smith, MA, MB BChir, MRCP, Department of Renal Medicine, Addenbrooke’s Hospital; Y.W. Chow, MD(USM), MRCP(UK), MRCPE, FRCP(Edinburgh), AM(MAL), Department of Medicine, Hospital Pantai Ayer Keroh Melaka; A.N. Chaudhry, MBBS, PhD, FRCP, FHEA, FACad MEd, Department of Renal Medicine, Addenbrooke’s Hospital; D.R. Jayne, MD, FRCP, Department of Renal Medicine, Addenbrooke’s Hospital. Address correspondence to Dr. A.J. Mohammad, Box 57, Renal Medicine, Addenbrooke’s Hospital, Hills Road, Cambridge, CB20QQ, UK. E-mail: aladdin.mohammad@med.lu.se. Accepted for publication June 9, 2015.
Afzal N. Chaudhry
From the Department of Renal Medicine, Addenbrooke’s Hospital, Cambridge, UK; Department of Clinical Sciences, Rheumatology, Lund University, Lund, Sweden; Department of Medicine, Hospital Pantai Ayer Keroh, Melaka, Malaysia. Supported by the Cambridge Biomedical Research Centre and The Swedish Society of Medicine (Svenska Läkarsällskapet). A.J. Mohammad, MD, PhD, Department of Renal Medicine, Addenbrooke’s Hospital, and Department of Clinical Sciences, Rheumatology, Lund University; R.M. Smith, MA, MB BChir, MRCP, Department of Renal Medicine, Addenbrooke’s Hospital; Y.W. Chow, MD(USM), MRCP(UK), MRCPE, FRCP(Edinburgh), AM(MAL), Department of Medicine, Hospital Pantai Ayer Keroh Melaka; A.N. Chaudhry, MBBS, PhD, FRCP, FHEA, FACad MEd, Department of Renal Medicine, Addenbrooke’s Hospital; D.R. Jayne, MD, FRCP, Department of Renal Medicine, Addenbrooke’s Hospital. Address correspondence to Dr. A.J. Mohammad, Box 57, Renal Medicine, Addenbrooke’s Hospital, Hills Road, Cambridge, CB20QQ, UK. E-mail: aladdin.mohammad@med.lu.se. Accepted for publication June 9, 2015.
David R.W. Jayne
From the Department of Renal Medicine, Addenbrooke’s Hospital, Cambridge, UK; Department of Clinical Sciences, Rheumatology, Lund University, Lund, Sweden; Department of Medicine, Hospital Pantai Ayer Keroh, Melaka, Malaysia. Supported by the Cambridge Biomedical Research Centre and The Swedish Society of Medicine (Svenska Läkarsällskapet). A.J. Mohammad, MD, PhD, Department of Renal Medicine, Addenbrooke’s Hospital, and Department of Clinical Sciences, Rheumatology, Lund University; R.M. Smith, MA, MB BChir, MRCP, Department of Renal Medicine, Addenbrooke’s Hospital; Y.W. Chow, MD(USM), MRCP(UK), MRCPE, FRCP(Edinburgh), AM(MAL), Department of Medicine, Hospital Pantai Ayer Keroh Melaka; A.N. Chaudhry, MBBS, PhD, FRCP, FHEA, FACad MEd, Department of Renal Medicine, Addenbrooke’s Hospital; D.R. Jayne, MD, FRCP, Department of Renal Medicine, Addenbrooke’s Hospital. Address correspondence to Dr. A.J. Mohammad, Box 57, Renal Medicine, Addenbrooke’s Hospital, Hills Road, Cambridge, CB20QQ, UK. E-mail: aladdin.mohammad@med.lu.se. Accepted for publication June 9, 2015.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Alemtuzumab as Remission Induction Therapy in Behçet Disease: A 20-year Experience
Aladdin J. Mohammad, Rona M. Smith, Yok W. Chow, Afzal N. Chaudhry, David R.W. Jayne
The Journal of Rheumatology Aug 2015, jrheum.141344; DOI: 10.3899/jrheum.141344